|
|
|
|
|||||
|
|
|
Readout of investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis, a frequent and serious side effect in cancer patients treated with immune checkpoint inhibitors, on track for Q2 2026
Seres operational focus on advancing live biotherapeutic programs for inflammatory and immune diseases
Company working to create meaningful partnerships with collaborators to support continued development of pipeline programs, including SER-155 for allogeneic hematopoietic stem cell transplant (allo-HSCT)
CAMBRIDGE, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Seres Therapeutics, Inc. (Nasdaq: MCRB), (Seres or the Company), a leading live biotherapeutics company, today reported fourth quarter and full year 2025 financial results and provided business updates.
“As highlighted in our recent announcements, we are prioritizing our promising inflammatory and immunology biotherapeutics portfolio, including SER-603 for inflammatory bowel disease,” said Richard Kender, Executive Chair and interim CEO of Seres. “We are on track to report clinical data from the fully enrolled investigator-sponsored study at Memorial Sloan Kettering Cancer Center evaluating SER-155 to treat immune checkpoint inhibitor-related enterocolitis in the second quarter of this year. This serious condition affects up to 50% of immune checkpoint-treated cancer patients, with rates varying based on cancer drug and treatment regimen, and represents a sizable therapeutic and commercial opportunity. Additionally, our SER-155 program for the prevention of serious bloodstream infections in patients undergoing allo-HSCT for blood cancer is Phase 2 ready, and we continue to seek funding to support further development.
“To advance these opportunities, we continue to judiciously manage our resources, focusing on progressing our prioritized programs, as we pursue partnerships and other funding sources. We are in discussion with collaborators who could potentially provide Seres with additional financial and other resources to support pipeline advancement and value creation.”
Recent Highlights
Financial Results
The Company has classified all historical operating results for the VOWST business within discontinued operations in the consolidated statements of operations for the comparative periods presented. There is no activity in the current period related to discontinued operations.
Cash and Cash Runway
As of December 31, 2025, Seres had $45.8 million in cash and cash equivalents, which includes net proceeds of $12.2 million raised in Q4 2025 through the Company’s at-the-market equity offering program. Based on Seres’ current cash position and operating plans, the Company expects to fund operations through the third quarter of 2026. The Company continues to evaluate further opportunities to extend its cash runway.
About Seres Therapeutics
Seres Therapeutics, Inc. (Nasdaq: MCRB) is a clinical-stage biotechnology company developing novel live biotherapeutics, with a focus on inflammatory and immune diseases. The Company led the development and FDA approval of VOWST™, the first orally administered microbiome therapeutic, which was subsequently divested to Nestlé Health Science. SER-155, which has received Breakthrough Therapy and Fast Track designations, is being advanced for patients undergoing allogeneic hematopoietic stem cell transplant (allo-HSCT), and is Phase 2 ready, pending receipt of funding. An investigator-sponsored trial of SER-155 is ongoing in immune checkpoint inhibitor–related enterocolitis (irEC) to further evaluate the potential breadth of the Company’s live biotherapeutic platform. SER-603, in development for irritable bowel disease, is designed to modulate the gastrointestinal microbiome and support mucosal barrier integrity by targeting inflammatory bacteria and associated metabolites. For more information, please visit www.serestherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements about: the design, timing and results of our clinical studies and data readouts; current or future product candidates and their potential impacts and outcomes; clinical development plans and commercial opportunities; communications with, feedback from, or submissions to the FDA; operating plans; cost reduction actions and their anticipated benefits; our cash runway; our ability to secure a strategic, R&D, or other partnership and/or generate or obtain additional capital, financing or other resources; our ability to operationalize a study upon receipt of any financing; our planned strategic focus; the anticipated timing of any of the foregoing; and other statements that are not historical fact. These forward-looking statements are based on management’s current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: (1) our need for additional funding; (2) our ability to continue as a going concern; (3) we have incurred significant losses, are not currently profitable and may never become profitable; (4) our cost reduction actions may not achieve their intended benefits, including an extended cash runway; (5) our limited operating history; (6) the expected payments from the VOSWT sale are subject to risks and uncertainties; (7) we may not be able to realize the anticipated benefits of the VOWST sale, and may face new challenges as a smaller, less diversified company; (8) we have in the past and may in the future receive notice of the failure to satisfy a continued listing rule from The Nasdaq Stock Market LLC; (9) our novel approach to therapeutic intervention; (10) our reliance on third parties to conduct our clinical trials and manufacture our product candidates; (11) our ability to achieve market acceptance necessary for commercial success; (12) the competition we will face; (13) our ability to protect our intellectual property; (14) impact of our recent management transitions and appointments and our ability, to retain key personnel; and (15) disruptions at the FDA or other government agencies. These and other important factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K to be filed with the Securities and Exchange Commission (SEC) on March 12, 2026, as well as our other reports filed with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
| SERES THERAPEUTICS, INC. | ||||||||
| CONSOLIDATED BALANCE SHEETS | ||||||||
| (Unaudited, in thousands, except share and per share data) | ||||||||
| December 31, | ||||||||
| 2025 | 2024 | |||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 45,766 | $ | 30,793 | ||||
| Accounts receivable due from SPN - related party | 360 | 2,068 | ||||||
| Accounts receivable | 157 | — | ||||||
| Prepaid expenses and other current assets (1) | 3,093 | 5,813 | ||||||
| Total current assets | 49,376 | 38,674 | ||||||
| Property and equipment, net | 7,635 | 11,534 | ||||||
| Operating lease assets | 72,483 | 80,903 | ||||||
| Restricted cash | 8,668 | 8,668 | ||||||
| Other non-current assets | 31 | 31 | ||||||
| Total assets | $ | 138,193 | $ | 139,810 | ||||
| Liabilities and Stockholder's Equity | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,682 | $ | 4,079 | ||||
| Accrued expenses and other current liabilities | 3,972 | 10,719 | ||||||
| Accrued liabilities due to SPN - related party | 3,278 | 17,750 | ||||||
| Operating lease liabilities | 10,390 | 8,674 | ||||||
| Total current liabilities | 19,322 | 41,222 | ||||||
| Operating lease liabilities, net of current portion | 72,576 | 82,966 | ||||||
| Other long-term liabilities | 2,077 | 1,838 | ||||||
| Total liabilities | 93,975 | 126,026 | ||||||
| Commitments and contingencies (Note 10) | ||||||||
| Stockholders’ equity: | ||||||||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2025 and 2024; no shares issued and outstanding at December 31, 2025 and 2024 | — | — | ||||||
| Common stock, $0.001 par value; 360,000,000 shares authorized at December 31, 2025 and 2024, respectively; 9,556,446 and 8,650,227 shares issued and outstanding at December 31, 2025 and 2024, respectively | 10 | 9 | ||||||
| Additional paid-in capital | 1,016,611 | 991,874 | ||||||
| Accumulated deficit | (972,403 | ) | (978,099 | ) | ||||
| Total stockholders’ equity | 44,218 | 13,784 | ||||||
| Total liabilities and stockholders’ equity | $ | 138,193 | $ | 139,810 | ||||
[1] Includes $0 as of December 31, 2025 and $2,683 as of December 31, 2024 of unbilled receivable from SPN (related party) related to certain costs of the transition services performed by the Company. See Note 3, Discontinued Operations and TSA, for further details.
| SERES THERAPEUTICS, INC. | ||||||||||||
| CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) | ||||||||||||
| (Unaudited, in thousands, except share and per share data) | ||||||||||||
| Year Ended December 31, | ||||||||||||
| 2025 | 2024 | 2023 | ||||||||||
| Revenue: | ||||||||||||
| Grant revenue | 789 | — | — | |||||||||
| Total revenue | 789 | — | — | |||||||||
| Operating expenses: | ||||||||||||
| Research and development expenses | $ | 49,060 | $ | 64,600 | $ | 117,597 | ||||||
| General and administrative expenses | 39,156 | 53,183 | 77,500 | |||||||||
| Manufacturing services | 6,544 | 3,532 | — | |||||||||
| Total operating expenses | 94,760 | 121,315 | 195,097 | |||||||||
| Loss from operations | (93,971 | ) | (121,315 | ) | (195,097 | ) | ||||||
| Other income (expense): | ||||||||||||
| Gain on sale of VOWST Business | 80,685 | 5,684 | — | |||||||||
| Interest income | 2,227 | 3,967 | 7,301 | |||||||||
| Interest expense | — | — | (2,468 | ) | ||||||||
| Other income (expense), net (2) | 16,755 | (14,107 | ) | 134 | ||||||||
| Total other income (expense), net | 99,667 | (4,456 | ) | 4,967 | ||||||||
| Net income (loss) from continuing operations | $ | 5,696 | $ | (125,771 | ) | $ | (190,130 | ) | ||||
| Net income from discontinued operations, net of tax | $ | — | $ | 125,907 | $ | 76,406 | ||||||
| Net income (loss) | $ | 5,696 | $ | 136 | $ | (113,724 | ) | |||||
| Net income (loss) from continuing operations per share attributable to common stockholders - basic | $ | 0.64 | $ | (16.20 | ) | $ | (29.71 | ) | ||||
| Net income from discontinued operations per share attributable to common stockholders - basic | $ | — | $ | 16.20 | $ | 11.94 | ||||||
| Net income (loss) per share attributable to common stockholders - basic | $ | 0.64 | $ | — | $ | (17.77 | ) | |||||
| Net income (loss) from continuing operations per share attributable to common stockholders - diluted | $ | 0.64 | $ | (16.20 | ) | $ | (29.71 | ) | ||||
| Net income from discontinued operations per share attributable to common stockholders - diluted | $ | — | $ | 16.20 | $ | 11.94 | ||||||
| Net income (loss) per share attributable to common stockholders - diluted | $ | 0.64 | $ | — | $ | (17.77 | ) | |||||
| Weighted average common shares outstanding - basic | 8,858,975 | 7,769,910 | 6,400,339 | |||||||||
| Weighted average common shares outstanding - diluted | 8,869,742 | 7,769,910 | 6,400,339 | |||||||||
| Other comprehensive income: | ||||||||||||
| Unrealized gain on investments, net of tax of $0 | — | — | 10 | |||||||||
| Currency translation adjustment | — | — | 2 | |||||||||
| Total other comprehensive income | — | — | 12 | |||||||||
| Comprehensive income (loss) | $ | 5,696 | $ | 136 | $ | (113,712 | ) | |||||
[2] Includes $13,311 and $6,292 for the years ended December 31, 2025 and 2024 related to reimbursement received from SPN (related party) for transition services provided by the Company.
Investor and Media Contact:
Carlo Tanzi, Ph.D.
Kendall Investor Relations
[email protected]
| 6 hours | |
| 7 hours | |
| Mar-02 | |
| Feb-12 | |
| Feb-12 | |
| Feb-12 | |
| Jan-06 | |
| Dec-29 | |
| Nov-24 | |
| Nov-05 | |
| Oct-30 | |
| Oct-29 | |
| Oct-14 | |
| Sep-23 | |
| Sep-09 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about Finviz Elite